SGLT-2 inhibitors can reduce the renal glucose threshold of T2DM patients and promote the excretion of excess glucose in urine by highly selectively inhibiting the reabsorption of glucose by SGLT-2 protein in the early portion of the proximal renal tubule (the S1 segment), so as to reduce the blood glucose level (7). Here, SLC5A2 is linked to type 2 diabetes mellitus.